Artara Therapeutics Inc (TARA)

Jan 13, 2025, 8:00 AM EST - 7 days ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Dec 14, 2024, 8:30 AM EST - 5 weeks ago

Protara Therapeutics: Rising From The Ashes

Dec 11, 2024, 4:05 PM EST - 5 weeks ago

Protara Announces Closing of $100 Million Public Offering

Dec 10, 2024, 5:00 PM EST - 5 weeks ago

Protara Therapeutics: Carving New Roads In Bladder Cancer

Dec 10, 2024, 3:55 PM EST - 5 weeks ago

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 9, 2024, 11:35 PM EST - 5 weeks ago

Protara Announces Pricing of $100 Million Public Offering

Dec 9, 2024, 4:01 PM EST - 6 weeks ago

Protara Announces Proposed Public Offering

Dec 5, 2024, 10:50 AM EST - 6 weeks ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Nov 15, 2024, 5:52 PM EST - 2 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 6, 2024, 8:00 AM EST - 2 months ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 21, 2024, 8:00 AM EDT - 3 months ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Sep 9, 2024, 8:05 AM EDT - 4 months ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:00 AM EDT - 4 months ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 3, 2024, 8:00 AM EDT - 4 months ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jun 24, 2024, 5:06 PM EDT - 7 months ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2024, 8:00 AM EDT - 8 months ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 2, 2024, 8:00 AM EDT - 9 months ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 5, 2024, 8:04 AM EDT - 10 months ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Apr 5, 2024, 8:02 AM EDT - 10 months ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Apr 5, 2024, 8:00 AM EDT - 10 months ago

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Mar 13, 2024, 8:00 AM EDT - 11 months ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 8:00 AM EST - 11 months ago

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:55 AM EST - 11 months ago

Protara: A Bombed Out Biotech With A Very Positive Skew

CGON

Jan 31, 2024, 7:30 AM EST - 1 year ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Nov 30, 2023, 8:30 AM EST - 1 year ago

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 20, 2023, 8:30 AM EDT - 1 year ago

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

May 4, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

May 2, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Apr 28, 2023, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

Mar 8, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 2, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Jan 30, 2023, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

Dec 1, 2022, 8:00 AM EST - 2 years ago

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

Sep 6, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 16, 2022, 7:14 AM EDT - 2 years ago

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

KIND

Aug 9, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

May 26, 2022, 5:11 PM EDT - 2 years ago

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

May 5, 2022, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

Mar 24, 2022, 8:00 AM EDT - 3 years ago

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

Mar 9, 2022, 7:30 AM EST - 3 years ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

Jan 10, 2022, 8:00 AM EST - 3 years ago

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

Jan 4, 2022, 8:00 AM EST - 3 years ago

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Nov 4, 2021, 8:00 AM EDT - 3 years ago

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

Oct 25, 2021, 4:45 PM EDT - 3 years ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 12, 2021, 9:43 AM EDT - 3 years ago

Why Protara Therapeutics Stock Is Rising Today